MoonLake Immunotherapeutics
MLTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, MoonLake Immunotherapeutics (MLTX) is listed under Biotechnology. With a market capitalization of $1.41B, it sits in small-cap territory. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Market Cap
$1.41B
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-5.57
EPS (TTM)
$-3.88
EPS (Fwd)
$-3.45
ROE
-60.8%
ROA
-33.9%
Cash
$394.0M
Total Debt
$75.7M
Free CF
-$120.4M
52W Change
-53.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $394.0M in cash comfortably exceeding the $75.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$120.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -60.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MLTX.